Patients initially diagnosed with tripe negative breast cancer that would not respond to hormones or Her 2 drug treatments would receive an oral research drug or placebo for 6 months prior to definitive breast surgery and observed every 2 months with breast ultrasound while undergoing treatments.

Patient must have histologically confirmed invasive triple-negative adenocarcinoma of the breast with tumor ages greater than 18 years old.